ĐÁNH GIÁ KẾT QUẢ VÀ TÍNH AN TOÀN LIỆU PHÁP LENVATINIB BƯỚC 01 TRÊN NGƯỜI BỆNH ĐỐI VỚI UNG THƯ BIỂU MÔ TẾ BÀO GAN KHÔNG THỂ PHẪU THUẬT

Abstract

Aims: Assess the effectiveness and safety of Lenvatinib as a first-line treatment for unresectable hepatocellular carcinoma. Material and Methods: Thirty patients with unresectable hepatocellular carcinoma were treated with Lenvatinib and assessed for early results, treatment effectiveness, and safety issues. Key research indices included disease control rate, progression-free survival (PFS), and adverse effects. Results: the majority had hepatitis B-related liver inflammation, accounting for 73.3%, while hepatitis C was present in 6.7%. The liver function of Child-Pugh class A scored 5 and 6 points, corresponding to 83.3% and 16.7%. The incidence of portal vein thrombosis was 53.8%, with VP2, VP3, VP4 rates of 11.5%, 11.5%, and 30.8%, respectively. Most patients were in good condition (ECOG 0-1), and AFP levels before treatment were ≥ 400 ng/mL in 73.3% of cases. Disease control rate was 83.3% according to mRECIST criteria, and median progression-free survival (PFS) was 7.0± 0.8 months; factors influencing PFS included ALBI score, pre-treatment AFP, and major blood vessel invasion. Adverse effects were rare and manageable. Conclusion: Lenvatinib as a first-line treatment is a promising intervention for treating unresectable hepatocellular carcinoma, ensuring patient safety.